Dr. Craig E. Devoe

Craig Devoe, MD, MHCM, is Chief of the Don Monti Division of Medical Oncology and Hematology and Associate Professor of Medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. Board certified in Medical Oncology, Dr. Devoe specializes in gastrointestinal malignancies (colorectal cancer, pancreatic cancer), and cutaneous malignancies (malignant melanoma) at the Monter Cancer Center where he maintains an active practice focused on providing compassionate, personalized, evidence-based multi-disciplinary care. In addition, Dr. Devoe is a research investigator through the Northwell Health Cancer Institute s NCORP (NCI Community Oncology Research Program) grant and industry-sponsored trials. He works closely with the Cancer Institute s clinical trials office in terms of medical oversight of processes and operations, having completed a training program in clinical research design through the Harvard School of Public Health. Dr. Devoe has served as a member of the Alliance Audit Committee performing oversight at other nationally based cancer programs. After earning his medical degree from the State University of New York (SUNY) at Stony Brook School of Medicine, Dr. Devoe trained in internal medicine at NYU Langone Long Island and completed his fellowship in Hematology/Oncology at SUNY Stony Brook. Dr. Devoe furthered his leadership and managerial skills by earning a master s in Health Care Management degree from the Harvard School of Public Health. Dr. Devoe is an active member of the American Medical Association and the American Society of Clinical Oncology.

Dr. Devoe is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Colorectal Cancer, Familial Colorectal Cancer, Melanoma, and Tissue Biopsy.

Dr. Devoe is board certified in American Board Of Internal Medicine/Hematology and American Board Of Internal Medicine/Medical Oncology. He is actively involved in clinical research, co-authoring 33 peer reviewed articles and participating in 3 clinical trials.